Zimmer Biomet Earnings Call Balances Growth and Risk

Zimmer Biomet Holdings ((ZBH)) has held its Q4 earnings call. Read on for the main highlights of the call.

Zimmer Biomet’s latest earnings call struck a cautiously optimistic tone, pairing strong product momentum and cash generation with a frank acknowledgment of near‑term execution risks. Management highlighted solid growth in core hip and knee franchises and record robotics demand, but tempered enthusiasm with warnings about salesforce disruption, pricing pressure, and fragile international markets.

Solid Top-Line Growth in Q4 and Full-Year 2025

Zimmer Biomet delivered a healthy finish to the year, with Q4 organic constant-currency sales up 5.4% and broad-based strength across regions. U.S. organic growth reached 5.7% and international markets grew 5.0%, driving full-year 2025 organic growth of 3.9% and underscoring resilient demand in core reconstructive procedures.

Joint Reconstruction Adoption Accelerates

The company showed notable traction in its joint replacement portfolio, particularly in the U.S. knees and hips businesses. U.S. knee revenue grew about 6% in Q4 with Persona OsteoTide achieving roughly 35% penetration, while U.S. hip revenue climbed nearly 8% with implant C1 now representing more than 35% of hip stems.

Robotics and Technology Spur Capital Sales

Technology and capital spending were a key bright spot as U.S. technology, data, bone cement, and surgical cells revenue rose more than 10% in Q4. Management called out the strongest robotic capital sales quarter in more than two years and pointed to continued expansion of robotics and navigation platforms, including the MBOS collaboration.

Cash Flow Remains a Core Strength

Zimmer Biomet continued to convert earnings into cash at a robust pace, reinforcing balance sheet flexibility. Q4 operating cash flow reached $517 million and free cash flow came in at $368 million, while full-year 2025 free cash flow of $1.172 billion grew more than 11% year over year.

EPS Expansion and Shrinking Share Count

Adjusted profitability improved despite pockets of cost and pricing pressure, supporting shareholder returns. Q4 adjusted diluted EPS rose 4.8% year over year to $2.42, full-year adjusted EPS reached $8.20, and the fully diluted share count fell to 198.1 million helped by $250 million of Q4 buybacks.

Capital Returns and Balance Sheet Strategy

The company is leaning into buybacks as a key capital allocation lever while preserving liquidity for growth. The board has authorized up to $1.5 billion of share repurchases, with $250 million executed in Q4 2025 and management signaling plans to repurchase up to $750 million of stock during 2026, supported by year-end cash of about $592 million.

Innovation Pipeline and Portfolio Upgrades

Management emphasized that previous portfolio gaps have largely been closed and highlighted a broadened innovation engine. The so-called “magnificent seven” platforms, iodine-coated devices including in Japan, the Oxford partial cementless knee, and MBOS with Monogram all feature in a pipeline that is now roughly three times larger than a few years ago with several 2026 launches planned.

U.S. Go-to-Market Revamp Underway

A major transformation of the U.S. sales model is in progress, aimed at driving higher growth over time but with acknowledged near-term risk. About one-third of the shift to a dedicated and specialized salesforce is complete, with the majority expected by the end of 2027 and plans to add more than 200 robotics specialists to better target segments such as sports, extremities, and ambulatory surgery centers.

Guidance Dialed Back on 2026 Growth

Zimmer Biomet cooled expectations for near-term revenue growth as it navigates internal and external transitions. Management now expects 2026 organic constant-currency revenue to increase just 1% to 3%, down from recent mid-single-digit trends, primarily reflecting execution risk from the U.S. salesforce overhaul and evolving go-to-market strategies abroad.

Salesforce Shift Brings Execution Risk

Leadership was explicit that the salesforce conversion will be a multi-year effort with potential disruption to near-term trends. Two-thirds of the U.S. transition remains ahead, and management framed the change as essential to capturing higher-growth procedure categories, even if it creates intermittent volatility in quarterly performance.

Pricing Pressure and Margin Compression

Price erosion and cost headwinds are expected to weigh on profitability in the coming year, despite operational improvements. Q4 consolidated pricing fell about 50 basis points, and 2026 guidance assumes up to 100 basis points of additional pricing pressure alongside a gross margin step-down to roughly 70%–71% and operating margins about 50 basis points below 2025 levels.

GAAP Earnings Hit by Charges

Reported results under GAAP lagged adjusted performance as the company absorbed several one-time items and higher financing costs. Q4 GAAP diluted EPS declined to $0.70 from $1.20 a year earlier, reflecting brand rationalization charges, workforce reduction and restructuring expenses, and increased interest tied to the Paragon 28 transaction.

Higher Interest Costs and Deal Integration

The financing of recent acquisitions and a higher rate environment are adding a noticeable drag below the operating line. Adjusted net interest and other non-operating expenses were $71 million higher year over year in Q4, and for 2026 the company expects roughly $295 million of such expenses as it absorbs debt from Paragon 28 and elevated borrowing costs.

International Markets Remain a Weak Link

Management described the international landscape as fragile, with several region-specific headwinds weighing on performance and visibility. Asia Pacific is expected to be soft, pressured by Japan’s biannual price cuts, changes to China’s commercial model, and continued tariffs that are already compressing margins and likely to remain uneven.

2026 Outlook and Forward-Looking Guidance

For 2026, Zimmer Biomet guided to 1%–3% organic constant-currency revenue growth, adjusted EPS of $8.30–$8.45, and free cash flow growth of 8%–10% with conversion approaching 80%. The outlook factors in a modest sales lift from Paragon 28 before it becomes organic, a small positive FX impact, up to 100 basis points of pricing erosion, lower operating margins, about $295 million in interest and other non-operating expense, an 18% tax rate, and a reduced share count of 194–195 million following up to $750 million of buybacks.

Zimmer Biomet’s earnings call presented a company in transition, balancing strong demand for new implants and robotics with the growing pains of a redesigned sales engine and tougher pricing and international conditions. For investors, the story is one of near-term margin and growth pressure set against a larger bet that innovation and channel specialization will unlock higher, more sustainable growth beyond 2026.